Writing the MNTA OTM calls has paid off big in the last 5 years, congratulations if you have taken that approach. I would be careful here with taking any sort of short position in the stock. Notwithstanding the fact that the Russell 2000 is likely to sell-off big if there any correction in the markets: (1) management's tone is exceptionally assertive that a decision is expected soon, (2) the FDA has signaled it feels it has been provided significant deference in this area, (3) competitors (Amphastar) are getting nervous, (4) Sanofi has come out and said that they expect generic lovenox competition in their 2012-2013 #'s....
Had the heparin scare not taken place and the immunogenecity concerns reared their ugly head, MNTA mL would have likely already been approved. We are in the 5th year of the FDA sitting on this ANDA, I think the odds of a decision are extremely high.
